| Title | Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial |
| Authors | Han, Guohong Yang, Jijin Shao, Guoliang Teng, Gaojun Wang, Maoqiang Yang, Jianyong Liu, Zhaoyu Feng, Gansheng Yang, Renjie Lu, Ligong Chao, Yee Wang, Jianhua |
| Affiliation | Fourth Mil Med Univ, Xijing Hosp, Xian 710032, Peoples R China. Second Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China. Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China. Southeast Univ, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China. Peoples Liberat Army Gen Hosp, Beijing, Peoples R China. Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China. China Med Univ, Shengjing Hosp, Shenyang, Peoples R China. Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan 430074, Peoples R China. Peking Univ, Beijing Canc Hosp, Beijing 100871, Peoples R China. Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China. Vet Gen Hosp, Taipei, Taiwan. Fudan Univ, Zhongshan Hosp, Dept Radiol, Shanghai 200433, Peoples R China. |
| Keywords | hepatocellular carcinoma sorafenib transarterial chemoembolization TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION RANDOMIZED CONTROLLED TRIAL ENDOTHELIAL GROWTH-FACTOR LIPIODOL CHEMOEMBOLIZATION ANGIOGENESIS MANAGEMENT EXPRESSION THERAPY KINASES COHORT |
| Issue Date | 2013 |
| Publisher | future oncology |
| Citation | FUTURE ONCOLOGY.2013,9,(3),403-410. |
| Abstract | Aim: The third interim results of the START trial showed encouraging safety and efficacy profiles, with a median time to progression of 9 months. This subgroup analysis presents results in Chinese patients enrolled in the START trial. Materials & methods: Sixty two Chinese patients (median age 52 years) with unresectable hepatocellular carcinoma had transarterial chemoembolization (TACE) performed with an emulsion of Lipiodol (R) (Guerbet, Paris, France) and doxorubicin (30-60 mg) followed by embolization with absorbable particles. Sorafenib (400 mg twice-daily) was administered continuously with dose holidays 4 days prior to and post TACE procedures. TACE was performed every 6-8 weeks and responses were assessed after 4-6 weeks and then every 3 months if no further TACE was indicated. Patients continued receiving sorafenib until disease progression or unacceptable toxicity occurred. Results: Thirty seven patients (59.68%) received no more than two TACE procedures. During sorafenib treatment (median duration 6.4 months; mean daily dose 787.6 mg), 75.8% of patients experienced adverse events, most commonly pyrexia (37.1%), diarrhea (27.4%), skin reactions (22.6%), alopecia (19.4%) and abnormal hepatic function (16.1%). The most common grade 3-4 adverse events were abnormal hepatic function (6.5%) and diarrhea (3.2%). The median time to progression and overall survival were 10.6 and 16.5 months, respectively, and the objective response and stable disease rates were 44.3 and 42.6%, respectively. Conclusion: The combination of the TACE and sorafenib proved both safe and effective in the treatment of Chinese patients with unresectable hepatocellular carcinoma. |
| URI | http://hdl.handle.net/20.500.11897/392071 |
| ISSN | 1479-6694 |
| DOI | 10.2217/FON.13.11 |
| Indexed | SCI(E) |
| Appears in Collections: | 北京肿瘤医院 |
